Efficacy and Safety of Bimatoprost for the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Three-Month, Open-Label Study in Community-Based Practices in Thailand Boonsong Wanichwecha-rungruang, MD*, Wallop Iemsomboon, MD**
* Glaucoma Services, Department of Ophthalmology, Institute of Undergraduate Medical Education, Department of Medical Services in affiliation with Rangsit University, Rajavithi Hospital ** Glaucoma Division, Department of Ophthalmology, Phramongkutklao Hospital, Phramongkutklao College of Medicine
Affiliation : The authors evaluated the effectiveness and safety of bimatoprost using an open-label, non-compara- tive, three-month, community-based surveillance study. Patients (n = 458) with open-angle glaucoma or ocular hypertension received bimatoprost 0.03% ophthalmic solution as monotherapy, replacement therapy or adjunctive therapy. Bimatoprost produced a rapid, significant (p < 0.0001) reduction in intraocular pressure: monotherapy (34.6% reduction); replacement therapy (16.4% reduction); adjunctive therapy (24.1% reduction). Bimatoprost enabled more patients to achieve their pre-defined target intraocular pressure (p < 0.0001), compared to previous treatments, and significantly lowered intraocular pressure, regardless of the patients’ baseline pressure level or history of pressure control. Bimatoprost was well-tolerated; the most commonly reported adverse event was conjunctival hyperaemia (19.9%). Most patients and ophthalmologists rated bimatoprost highly, compared to previously used treatments. The authors concluded that bimatoprost is an effective, well-tolerated treatment for lowering intraocular pressure in Thai patients with open-angle glaucoma or ocular hypertension.
Keywords : Bimatoprost, Open angle glaucoma, Ocular hypertension, Intraocular pressure, Thailand
